Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RHOA | P61586 | 1/20 | 0.32 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.31 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.30 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.30 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.30 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.30 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6007485 | 0.76 | KDM4E (0.35) | PDE10A | |
| SCHEMBL5767894 | 0.71 | ADRA2A (0.39) | RHOAADRA2AADRA2CADRA1DADRA1A | |
| SCHEMBL7249060 | 0.71 | RHOA (0.32) | RHOAADRA2AADRA2CADRA1DADRA1A | |
| SCHEMBL5272070 | 0.67 | KDM4E (0.35) | — | |
| SCHEMBL28094081 | 0.66 | DYRK1A (0.42) | RHOAADRA2AADRA2CADRA1DADRA1A | |
| SCHEMBL20482144 | 0.64 | ADRA2A (0.33) | RHOAADRA2AADRA2CADRA1DADRA1A | |
| SCHEMBL2793390 | 0.62 | LMNA (0.33) | — | |
| SCHEMBL4307834 | 0.62 | MAPT (0.52) | ADRA1A | |
| SCHEMBL4677179 | 0.61 | PDE10A (0.69) | PDE10A | |
| SCHEMBL4198122 | 0.60 | KDM4E (0.36) | RHOAADRA2AADRA2CADRA1DADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1381614-B1 | ANTIDEPRESSANT AZAHETEROCYCLYLMETHYL DERIVATIVES OF 2,3-DIHYDRO-1,4-DIOXINO¬2,3-f|QUINOXALINE | WYETH CORP (US) | 2006-08-02 | — | — | EP | disclosed |
| US-7008944-B2 | Antidepressant azaheterocyclylmethyl derivatives of 2,3-dihydro-1,4-Dioxino[2,3-f]quinoxaline | WYETH (US) | 2006-03-07 | — | — | US | disclosed |
| US-20040077652-A1 | Treating obsessive compulsive disorder, panic attacks, sexual disorders, eating disorders, obesity, drug abuse and ethanol or cocaine dependence; anxiolytic agents | WYETH | 2004-04-22 | — | — | US | disclosed |
| EP-1381614-A2 | ANTIDEPRESSANT AZAHETEROCYCLYLMETHYL DERIVATIVES OF 2,3-DIHYDRO-1,4-DIOXINO 2,3-f]QUINOXALINE | Wyeth (US) | 2004-01-21 | — | — | EP | disclosed |
| US-6617327-B2 | For therapy of depression and other diseases such as obsessive compulsive disorder, panic attacks, generalized anxiety disorder, social anxiety disorder, sexual dysfunction, eating disorders, obesity, addictive disorders | WYETH | 2003-09-09 | — | — | US | disclosed |
| US-20020183329-A1 | Antidepressant azaheterocyclylmethyl derivatives of 2,3-dihydro-1,4-dioxino[2,3-f]quinoxaline | WYETH | 2002-12-05 | — | — | US | disclosed |
| WO-2002088144-A2 | ANTIDEPRESSANT AZAHETEROCYCLYLMETHYL DERIVATIVES OF 2,3-DIHYDRO-1,4-DIOXINO[2,3-f]QUINOXALINE | WYETH (US) | 2002-11-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077652-A1 | Treating obsessive compulsive disorder, panic attacks, sexual disorders, eating disorders, obesity, drug abuse and ethanol or cocaine dependence; anxiolytic agents | OPRD1, DRD1, ADH1A | RHOA 4729/4885PDE10A 238/4885ADRA2A 261/4885 |
| US-20020183329-A1 | Antidepressant azaheterocyclylmethyl derivatives of 2,3-dihydro-1,4-dioxino[2,3-f]quinoxaline | OPRD1, OPRK1, DRD2 | RHOA 4318/4885PDE10A 789/4885ADRA2A 575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.